Plasma polymerized nanoparticles effectively deliver dual siRNA and drug therapy in vivo

• Published in: Scientific reports Vol. 10; no. 1; p. 12836
• Main Authors: Michael, Praveesuda, Lam, Yuen Ting, Filipe, Elysse C., Tan, Richard P., Chan, Alex H. P., Lee, Bob S. L., Feng, Nicolas, Hung, Juichien, Cox, Thomas R., Santos, Miguel, Wise, Steven G.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 30.07.2020; Nature Publishing Group
• Subjects: 631/61; 639/301; 639/766; 639/925; Animals; Antineoplastic Agents - administration & dosage; Breast cancer; Breast Neoplasms - pathology; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug therapy; Female; Humanities and Social Sciences; Mice; multidisciplinary; Nanoparticles; Paclitaxel; Paclitaxel - administration & dosage; Plasma; Polymerization; RNA, Small Interfering - administration & dosage; RNA, Small Interfering - pharmacology; Science; Science (multidisciplinary); siRNA; Tumor Microenvironment - drug effects; Tumors; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A - metabolism
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-020-69591-x

Multifunctional nanocarriers (MNCs) promise to improve therapeutic outcomes by combining multiple classes of molecules into a single nanostructure, enhancing active targeting of therapeutic agents and facilitating new combination therapies. However, nanocarrier platforms currently approved for clinical use can still only carry a single therapeutic agent. The complexity and escalating costs associated with the synthesis of more complex MNCs have been major technological roadblocks in the pathway for clinical translation. Here, we show that plasma polymerized nanoparticles (PPNs), synthesised in reactive gas discharges, can bind and effectively deliver multiple therapeutic cargo in a facile and cost-effective process compatible with up scaled commercial production. Delivery of siRNA against vascular endothelial growth factor (siVEGF) at extremely low concentrations (0.04 nM), significantly reduced VEGF expression in hard-to-transfect cells when compared with commercial platforms carrying higher siRNA doses (6.25 nM). PPNs carrying a combination of siVEGF and standard of care Paclitaxel (PPN-Dual) at reduced doses (< 100 µg/kg) synergistically modulated the microenvironment of orthotopic breast tumors in mice, and significantly reduced tumor growth. We propose PPNs as a new nanomaterial for delivery of therapeutics, which can be easily functionalised in any laboratory setting without the need for additional wet-chemistry and purification steps.